Advanced search
Publication Cover
The International Journal for the Psychology of Religion Volume 33, 2023 - Issue 4: Psychedelics and Mystical-type Experiences: Relevance and implications for the Psychology of Religion and Spirituality
Submit an article Journal homepage
9,411
Views
0
CrossRef citations to date
0
Altmetric
Articles

Altered States of Consciousness During Ceremonial San Pedro UseOpen DataOpen Materials

Arne Bohna Behavioural Science Institute, Radboud University, Nijmegen, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-2599-3489View further author information
ORCID Icon,
Michiel H. H. Kiggena Behavioural Science Institute, Radboud University, Nijmegen, The Netherlands;b Stevig Specialized and Forensic Care for People with Intellectual Disabilities, Dichterbij, Oostrum, The NetherlandsCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0900-0157View further author information
ORCID Icon,
Malin V. Uthaugc The Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College, London, UK;d Department of Clinical Psychological Science, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The NetherlandsORCID Iconhttps://orcid.org/0000-0001-7903-1325View further author information
ORCID Icon,
Kim I. M. van Oorsouwd Department of Clinical Psychological Science, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The NetherlandsORCID Iconhttps://orcid.org/0000-0001-9148-5282View further author information
ORCID Icon,
Johannes G. Ramaekerse Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-4553-376XView further author information
ORCID Icon &
Hein T. van Schiea Behavioural Science Institute, Radboud University, Nijmegen, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-1149-5198View further author information
ORCID Icon
Pages 309-331 | Published online: 05 Dec 2022

References

  • Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews, 113, 179–189. https://doi.org/10.1016/j.neubiorev.2020.03.017
  • Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021). Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacology & Translational Science, 4(2), 543–552. https://doi.org/10.1021/acsptsci.1c00018
  • Akindele, M. O., Evans, J. I., & Oswald, I. (1970). Mono-amine oxidase inhibitors, sleep and mood. Electroencephalography and Clinical Neurophysiology, 29(1), 47–56. https://doi.org/10.1016/0013-4694(70)90078-7
  • Araújo, A. M., Carvalho, F., de Lourdes Bastos, M., De Pinho, P. G., & Carvalho, M. (2015). The hallucinogenic world of tryptamines: An updated review. Archives of Toxicology, 89(8), 1151–1173. https://doi.org/10.1007/s00204-015-1513-x
  • Barile, F. A. (2019). Barile’s Clinical Toxicology: Principles and Mechanisms. CRC Press.
  • Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S., Johnson, M. W., & Griffiths, R. R. (2016). The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 30(12), 1279–1295. https://doi.org/10.1177/0269881116678781
  • Barrett, F. S., & Griffiths, R. R. (2017). Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. Behavioral Neurobiology of Psychedelic Drugs, 393–430. https://doi.org/10.1007/7854_2017_474
  • Bienemann, B., Ruschel, N. S., Campos, M. L., Negreiros, M. A., Mograbi, D. C., & Carrà, G. (2020). Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. PloS One, 15(2), e0229067. https://doi.org/10.1371/journal.pone.0229067
  • Blanchette, I., & Richards, A. (2010). The influence of affect on higher level cognition: A review of research on interpretation, judgement, decision making and reasoning. Cognition & Emotion, 24(4), 561–595. https://doi.org/10.1080/02699930903132496
  • Borsboom, D., & Cramer, A. O. (2013). Network analysis: An integrative approach to the structure of psychopathology. Annual Review of Clinical Psychology, 9(1), 91–121. https://doi.org/10.1146/annurev-clinpsy-050212-185608
  • Bravo, G., & Grob, C. (1989). Shamans, sacraments, and psychiatrists. Journal of Psychoactive Drugs, 21(1), 123–128. https://doi.org/10.1080/02791072.1989.10472149
  • Bruhn, J. G., Ei-Seedi, H. R., Stephanson, N., Beck, O., & Shulgin, A. T. (2008). Ecstasy analogues found in cacti. Journal of Psychoactive Drugs, 40(2), 219–222. https://doi.org/10.1080/02791072.2008.10400635
  • Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278. https://doi.org/10.1177/0269881116662634
  • Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016). The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychological Medicine, 46(7), 1379–1390. https://doi.org/10.1017/S0033291715002901
  • Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725–731. https://doi.org/10.1177/0269881118754710
  • Carod-Artal, F. J., & Vazquez-Cabrera, C. B. (2006). Mescaline and the San Pedro cactus ritual: Archaeological and ethnographic evidence in northern Peru. Revista de Neurologia, 42(8), 489–498. PMID: 16625512. https://doi.org/10.33588/rn.4208.2006040
  • Cassels, B. K., & Sáez-Briones, P. (2018). Dark classics in chemical neuroscience: Mescaline. ACS Chemical Neuroscience, 9(10), 2448–2458. https://doi.org/10.1021/acschemneuro.8b00215
  • Cohen, K., Weizman, A., & Weinstein, A. (2019). Positive and negative effects of cannabis and cannabinoids on health. Clinical Pharmacology & Therapeutics, 105(5), 1139–1147. https://doi.org/10.1002/cpt.1381
  • Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
  • De Rios, M. D. (1977). Plant hallucinogens and the religion of the Mochica—An ancient Peruvian people. Economic Botany, 31(2), 189–203. https://doi.org/10.1007/BF02866590
  • Dinis-Oliveira, R. J., Pereira, C. L., & da Silva, D. D. (2019). Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: Clinical and forensic repercussions. Current Molecular Pharmacology, 12(3), 184. https://doi.org/10.2174/1874467211666181010154139
  • Dittrich, A. (1998). The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry, 31(S 2), 80–84. https://doi.org/10.1055/s-2007-979351
  • Dobkin, M. (1968). Trichocereus pachanoi: A mescaline cactus used in folk healing in Peru. Economic Botany, 22(2), 191–194. https://doi.org/10.1007/BF02860562
  • Dorsen, C., Palamar, J., & Shedlin, M. G. (2019). Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: An exploratory study. Addiction Research & Theory, 27(2), 68–75. https://doi.org/10.1080/16066359.2018.1455187
  • Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 11(1), 1–10. https://doi.org/10.1038/s41398-021-01706-y
  • Elsey, J. W. (2017). Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy. Drug Science, Policy and Law, 3, 205032451772323. https://doi.org/10.1177/2050324517723232
  • Erowid. (n.d.) Psychoactive Cacti. Erowid. https://erowid.org/plants/cacti/
  • Farmer, S., Slavin, M. N., Loflin, M. J., Luba, R., & Earleywine, M. (2019). Aversiveness and meaningfulness of uncomfortable experiences with edible cannabis. Journal of Psychoactive Drugs, 51(5), 413–420. https://doi.org/10.1080/02791072.2019.1645371
  • Ferrara, M. S. (2021). Peak-experience and the entheogenic use of cannabis in world religions. Journal of Psychedelic Studies, 4(3), 179–191. https://doi.org/10.1556/2054.2020.00122
  • Fotiou, E. (2020). The role of indigenous knowledges in psychedelic science. Journal of Psychedelic Studies, 4(1), 16–23. https://doi.org/10.1556/2054.2019.031
  • Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157–164. https://doi.org/10.2174/1874473708666150107121331
  • Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016). Clinical applications of hallucinogens: A review. Experimental and Clinical Psychopharmacology, 24(4), 229. https://doi.org/10.1037/pha0000084
  • Glass‐coffin, B. (2010). Shamanism and San Pedro through time: Some notes on the archaeology, history, and continued use of an entheogen in northern Peru. Anthropology of Consciousness, 21(1), 58–82. https://doi.org/10.1111/j.1556-3537.2010.01021.x
  • Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021). Psychedelic harm reduction and integration: A transtheoretical model for clinical practice. Frontiers in Psychology, 12, 710. https://doi.org/10.3389/fpsyg.2021.645246
  • Gottlieb, A. (1977). Peyote and other psychoactive cacti. Kistone Press.
  • Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649–665. https://doi.org/10.1007/s00213-011-2358-5
  • Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/10.1007/s00213-006-0457-5
  • Guthrie, L. (2021). A phenomenology of challenging psychedelic experiences: From relational trauma to relational healing [ Doctoral dissertation, Duquesne University]. https://dsc.duq.edu/etd/2011
  • Guttmann, E. (1936). Artificial psychoses produced by mescaline. The Journal of Mental Science, 82(338), 203–221. https://doi.org/10.1192/bjp.82.338.203
  • Haidt, J., Patrick Seder, J., & Kesebir, S. (2008). Hive psychology, happiness, and public policy. The Journal of Legal Studies, 37(S2), S133–156. https://doi.org/10.1086/529447
  • Hapke, H. J., & Strathmann, W. (1995). Pharmacological effects of hordenine. DTW Deutsche Tierarztliche Wochenschrift, 102(6), 228–232. PMID: 8582256.
  • Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 30(12), 1259–1267. https://doi.org/10.1177/0269881116677852
  • Hartogsohn, I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3, 2050324516683325. https://doi.org/10.1177/2050324516683325
  • Healy, C. J. (2021). The acute effects of classic psychedelics on memory in humans. Psychopharmacology, 1–15. https://doi.org/10.1007/s00213-020-05756-w
  • Heaven, R. (2010). Hummingbirds journey to god: Perspective on san pedro, the cactus of vision & andean soul healing methods. John Hunt Publishing.
  • Heaven, R. (2012). Cactus of mystery: The shamanic powers of the Peruvian San Pedro cactus. Simon and Schuster.
  • Hirschfeld, T., & Schmidt, T. T. (2020). How it feels to be on: LSD, Psilocybin, DMT or Ayahuasca (Version1). figshare. https://doi.org/10.6084/m9.figshare.13056104.v1
  • Hoehn-Saric, R., & McLeod, D. R. (1988). The peripheral sympathetic nervous system: Its role in normal and pathologic anxiety. The Psychiatric Clinics of North America, 11(2), 375–386. https://doi.org/10.1016/S0193-953X(18)30504-5
  • Holze, F., Ley, L., Muller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K., Varghese, N., Eckert, A., & Liechti, M. E. (2022). Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 47(6), 1180–1187. https://doi.org/10.1038/s41386-022-01297-2
  • Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2021). Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 46(3), 537–544. https://doi.org/10.1038/s41386-020-00883-6
  • Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020). Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology, 45(3), 462–471. https://doi.org/10.1038/s41386-019-0569-3
  • Isbell, H. (1959). Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia, 1(1), 29–38. https://doi.org/10.1007/BF00408109
  • Iversen, S. D., & Iversen, L. L. (2007). Dopamine: 50 years in perspective. Trends in Neurosciences, 30(5), 188–193. https://doi.org/10.1016/j.tins.2007.03.002
  • Jay, M. (2019). Mescaline: A global history of the first psychedelic. Yale University Press.
  • Jilek, W. G. (1982). Altered states of consciousness in North American Indian ceremonials. Ethos, 10(4), 326–343. https://doi.org/10.1525/eth.1982.10.4.02a00040
  • Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83–102. https://doi.org/10.1016/j.pharmthera.2018.11.010
  • Johnstad, P. G. (2020). Cannabis as entheogen: Survey and interview data on the spiritual use of cannabis. Journal of Cannabis Research, 2(1), 1–17. https://doi.org/10.1186/s42238-020-00032-2
  • Jones, P. N. (2005). The American Indian Church and its sacramental use of peyote: A review for professionals in the mental-health arena. Mental Health, Religion & Culture, 8(4), 277–290. https://doi.org/10.1080/13674670412331304348
  • Keller, W. J., & Ferguson, G. G. (1977). Effects of 3, 4‐dimethoxyphenethylamine derivatives on monoamine oxidase. Journal of Pharmaceutical Sciences, 66(7), 1048–1050. https://doi.org/10.1002/jps.2600660741
  • Kettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021). Psychedelic communitas: Intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Frontiers in Pharmacology, 12, 234. https://doi.org/10.3389/fphar.2021.623985
  • Khan, M. Z., & Nawaz, W. (2016). The emerging roles of human trace amines and human trace amine-associated receptors (hTaars) in central nervous system. Biomedecine & Pharmacotherapie, 83, 439–449. https://doi.org/10.1016/j.biopha.2016.07.002
  • Kovacic, P., & Somanathan, R. (2009). Novel, unifying mechanism for mescaline in the central nervous system: Electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships. Oxidative Medicine and Cellular Longevity, 2(4), 181–190. https://doi.org/10.4161/oxim.2.4.9380
  • Krebs, T. S., & Johansen, P. Ø. (2013). Over 30 million psychedelic users in the United States. F1000Research, 2. https://doi.org/10.12688/f1000research.2-98.v1
  • Kuc, J., Kettner, H., Rosas, F., Erritzoe, D., Haijen, E., Kaelen, M., Nutt, D., & Carhart-Harris, R. L. (2022). Psychedelic experience dose-dependently modulated by cannabis: Results of a prospective online survey. Psychopharmacology, 239(5), 1425–1440. https://doi.org/10.1007/s00213-021-05999-1
  • Letheby, C., & Gerrans, P. (2017). Self unbound: Ego dissolution in psychedelic experience. Neuroscience of Consciousness, 2017(1), nix016. https://doi.org/10.1093/nc/nix016
  • Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017). Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology, 234(9–10), 1499–1510. https://doi.org/10.1007/s00213-016-4453-0
  • MacLean, K. A., Leoutsakos, J. M. S., Johnson, M. W., & Griffiths, R. R. (2012). Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion, 51(4), 721–737. https://doi.org/10.1111/j.1468-5906.2012.01685.x
  • Majić, T., Schmidt, T. T., & Gallinat, J. (2015). Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Journal of Psychopharmacology, 29(3), 241–253. https://doi.org/10.1177/0269881114568040
  • MATLAB. (2017). Version 9.2.0 (R2017a). The MathWorks Inc.
  • Microdosinginstitute. (n.d.) Microdosing San Pedro (mescaline). Microdosinginstitute. https://microdosinginstitute.com/microdosing-101/substances/san-pedro-mescaline/
  • Miller, G. M. (2011). The emerging role of trace amine‐associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. Journal of Neurochemistry, 116(2), 164–176. https://doi.org/10.1111/j.1471-4159.2010.07109.x
  • Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F. M., & Berkovich-Ohana, A. (2018). Psychedelics, meditation, and self-consciousness. Frontiers in Psychology, 9, 1475. https://doi.org/10.3389/fpsyg.2018.01475
  • Móró, L., Simon, K., Bárd, I., & Rácz, J. (2011). Voice of the psychonauts: Coping, life purpose, and spirituality in psychedelic drug users. Journal of Psychoactive Drugs, 43(3), 188–198. https://doi.org/10.1080/02791072.2011.605661
  • Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002
  • Nichols, D. E., & Barker, E. L. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478
  • Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Frontiers in Human Neuroscience, 10, 269. https://doi.org/10.3389/fnhum.2016.00269
  • Ogunbodede, O., McCombs, D., Trout, K., Daley, P., & Terry, M. (2010). New mescaline concentrations from 14 taxa/cultivars of Echinopsis spp.(cactaceae)(“san Pedro”) and their relevance to shamanic practice. Journal of Ethnopharmacology, 131(2), 356–362. https://doi.org/10.1016/j.jep.2010.07.021
  • Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M., Raz, A., & Veissiere, S. P. (2020). Tripping on nothing: Placebo psychedelics and contextual factors. Psychopharmacology, 237(5), 1371–1382. https://doi.org/10.1007/s00213-020-05464-5
  • Phelps, E. A. (2006). Emotion and cognition: Insights from studies of the human amygdala. Annual Review of Psychology, 57(1), 27–53. https://doi.org/10.1146/annurev.psych.56.091103.070234
  • Polito, V., Langdon, R., & Brown, J. (2010). The experience of altered states of consciousness in shamanic ritual: The role of pre-existing beliefs and affective factors. Consciousness and Cognition, 19(4), 918–925. https://doi.org/10.1016/j.concog.2010.05.013
  • Pontual, A. A. D. D., Tófoli, L. F., Corradi-Webster, C. M., van Oorsouw, K., Delgado, A. R. O., & Ramaekers, J. G. (2022). The influence of ceremonial settings on mystical and challenging experiences occasioned by ayahuasca: A survey among ritualistic and religious ayahuasca users. Frontiers in Psychology, 4239. https://doi.org/10.3389/fpsyg.2022.857372
  • Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017). The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Current Biology, 27(3), 451–457. https://doi.org/10.1016/j.cub.2016.12.030
  • Preller, K. H., & Vollenweider, F. X. (2016). Phenomenology, structure, and dynamic of psychedelic states. Behavioral Neurobiology of Psychedelic Drugs, 221–256. https://doi.org/10.1007/7854_2017_477
  • PsychonautWiki. (n.d.) Mescaline. PsychonautWiki. https://psychonautwiki.org/wiki/Mescaline
  • Ray, T. S., & Manzoni, O. J. (2010). Psychedelics and the human receptorome. PloS One, 5(2), e9019. https://doi.org/10.1371/journal.pone.0009019
  • R Core Team. (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing. https://www.R-project.org/
  • Ribeiro, S. (2018). Whole organisms or pure compounds? Entourage effect versus drug specificity. In B. C. Labate & C. Cavnar (Eds.), Plant medicines, healing and psychedelic science (pp. 133–149). Springer.
  • Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016). Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. European Neuropsychopharmacology, 26(8), 1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001
  • Rubin-Kahana, D. S., Hassan, A. N., & Le Foll, B. (2021). Posttraumatic stress disorder after a psychedelic experience, a case report. Journal of Addiction Medicine, 15(3), 248–251. https://doi.org/10.1097/ADM.0000000000000734
  • Russell, J. A. (2003). Core affect and the psychological construction of emotion. Psychological Review, 110(1), 145. https://doi.org/10.1037/0033-295X.110.1.145
  • Samorini, G. (2019). The oldest archeological data evidencing the relationship of Homo sapiens with psychoactive plants: A worldwide overview. Journal of Psychedelic Studies, 3(2), 63–80. https://doi.org/10.1556/2054.2019.008
  • Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 36(3), 258–272. https://doi.org/10.1177/02698811211069100
  • Schmid, Y., & Liechti, M. E. (2018). Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology, 235(2), 535–545. https://doi.org/10.1007/s00213-017-4733-3
  • Schultes, R. E., Hofmann, A., & Rätsch, C. (1992). Plants of the gods: Their sacred, healing, and hallucinogenic powers. Healing Arts Press.
  • Schulz, A., & Vögele, C. (2015). Interoception and stress. Frontiers in Psychology, 6, 993. https://doi.org/10.3389/fpsyg.2015.00993
  • Scuro, J., & Rodd, R. (2015). Neo-shamanism. In H. P. P. Gooren (Ed.), Encyclopedia of Latin American religions (pp. 1–6). Springer.
  • Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2020). Inhaled 5-methoxy-N, N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. Journal of Psychedelic Studies, 4(2), 114–122. https://doi.org/10.1556/2054.2019.033
  • Sharrock, D. (2018, April). Smoky boundaries, permeable selves: Exploring the self in relationship with the Amazonian jungle tobacco, Mapacho. Anthropological Forum, 28(2), 146–157. Routledge. https://doi.org/10.1080/00664677.2018.1419934
  • Sociodelic. (2017). What is peyote? (Mescaline). Sociodelic. https://www.sociedelic.com/what-is-peyote-mescaline/
  • Sotnikova, T. D., Beaulieu, J. M., Espinoza, S., Masri, B., Zhang, X., Salahpour, A., Barak, L. S., Caron, M. G., Gainetdinov, R. R., & Bartolomucci, A. (2010). The dopamine metabolite 3-methoxytyramine is a neuromodulator. PloS One, 5(10), e13452. https://doi.org/10.1371/journal.pone.0013452
  • Stanfill, S. B., da Silva, A. L. O., Lisko, J. G., Lawler, T. S., Kuklenyik, P., Tyx, R. E., Peuchen, E. H., Richter, P., & Watson, C. H. (2015). Comprehensive chemical characterization of Rapé tobacco products: Nicotine, un-ionized nicotine, tobacco-specific N′-nitrosamines, polycyclic aromatic hydrocarbons, and flavor constituents. Food and Chemical Toxicology, 82, 50–58. https://doi.org/10.1016/j.fct.2015.04.016
  • Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2020). Set and setting: A randomized study of different musical genres in supporting psychedelic therapy. ACS Pharmacology & Translational Science, 4(2), 472–478. https://doi.org/10.1021/acsptsci.0c00187
  • Studerus, E., Gamma, A., Vollenweider, F. X., & Bell, V. (2010). Psychometric evaluation of the altered states of consciousness rating scale (OAV). PloS One, 5(8), e12412. https://doi.org/10.1371/journal.pone.0012412
  • Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. Journal of Psychopharmacology, 25(11), 1434–1452. https://doi.org/10.1177/0269881110382466
  • Thomason, T. C. (2010). The role of altered states of consciousness in Native American healing. Journal of Rural Community Psychology, E13(1), 1–11.
  • Torres, C. M. (1995). Archaeological evidence for the antiquity of psychoactive plant use in the Central Andes. Annuli Dei Musei Civici Roverero, 11, 291–326.
  • Tripsitter. (2021). Mescaline: Peyote, San Pedro, & Peruvian Torch Cactus. Tripsitter. https://tripsitter.com/mescaline/
  • Trulson, M. E., Crisp, T., & Henderson, L. J. (1983). Mescaline elicits behavioral effects in cats by an action at both serotonin and dopamine receptors. European Journal of Pharmacology, 96(1–2), 151–154. https://doi.org/10.1016/0014-2999(83)90544-7
  • Turner, D. M. (1994). The essential psychedelic guide. Panther Press.
  • Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021). The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology, 02698811211013583. https://doi.org/10.1177/02698811211013583
  • Uthaug, M. V., Mason, N. L., Toennes, S. W., Reckweg, J. T., de Sousa Fernandes Perna, E. B., Kuypers, K. P. C., van Oorsouw, K., Riba, J., & Ramaekers, J. G. (2021). A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology, 238(7), 1899–1910. https://doi.org/10.1007/s00213-021-05817-8
  • Uthaug, M. V., Van Oorsouw, K., Kuypers, K. P. C., Van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018). Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology, 235(10), 2979–2989. https://doi.org/10.1007/s00213-018-4988-3
  • Van Oorsouw, K. I., Toennes, S., & Ramaekers, J. G. (2022). Therapeutic effects of an ayahuasca analogue in clinically depressed patients: A longitudinal observational study. Psychopharmacology, 1–14.
  • Van Oorsouw, K. I., Uthaug, M. V., Mason, N. L., Broers, N. J., & Ramaekers, J. G. (2021). Sub-acute and long-term effects of ayahuasca on mental health and well-being in healthy ceremony attendants: A replication study. Journal of Psychedelic Studies, 5(2), 103–113. https://doi.org/10.1556/2054.2021.00174
  • Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Babler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport, 9(17), 3897–3902. https://doi.org/10.1097/00001756-199812010-00024
  • Watson-Jones, R. E., & Legare, C. H. (2016). The social functions of group rituals. Current Directions in Psychological Science, 25(1), 42–46. https://doi.org/10.1177/0963721415618486
  • Wei, T., & Simko, V. (2021). R package ‘corrplot’: Visualization of a correlation matrix. (Version 0.90). https://github.com/taiyun/corrplot
  • Winkelman, M. J. (2007). Shamanic guidelines for psychedelic medicine. psychedelic medicine: New evidence for hallucinogenic substances as treatments (Vol. 2). Praeger/Greenwood Publishers.
  • Winstock, A., Mitcheson, L., Ramsey, J., Davies, S., Puchnarewicz, M., & Marsden, J. (2011). Mephedrone: Use, subjective effects and health risks. Addiction, 106(11), 1991–1996. https://doi.org/10.1111/j.1360-0443.2011.03502.x
  • Wise, R. A. (2004). Dopamine, learning and motivation. Nature Reviews: Neuroscience, 5(6), 483–494. https://doi.org/10.1038/nrn1406
  • Wolff, T. J. (2020). The touristic use of Ayahuasca in Peru. Springer Fachmedien Wiesbaden.
  • Yaden, D. B., & Griffiths, R. R. (2020). The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science, 4(2), 568–572. https://doi.org/10.1021/acsptsci.0c00194
  • Zamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, E., & Tagliazucchi, E. (2018). The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines. Frontiers in Integrative Neuroscience, 12, 54. https://doi.org/10.3389/fnint.2018.00054
  • Zamnesia. (n.d.) The ultimate mescaline cactus guide. Zamnesia. https://www.zamnesia.com/content/698-mescaline-cacti

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.